Firm News
Wiggin and Dana Client Rallybio Raises $145 Million in Series B Financing
Wiggin and Dana represented its client, Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, in raising $145 million in its Series B financing led by Pivotal bioVenture Partners. Other investors participating in the financing include Viking Global Investors, TPGโs The Rise Fund, F-Prime Capital, funds managed by Tekla Capital Management LLC, Solasta Ventures, Fairview Capital, Mitsui & Co. Global Investment Inc., 5AM Ventures, Canaan Partners, New Leaf Venture Partners and Connecticut Innovations.
To learn more, click here.